IGC — Form 10-Q Summary
Business context and period: India Globalization Capital, Inc. (the filing’s name; now identified in the request as IGC Pharma, Inc.) reported the three months ended June 30, 2017, its fiscal first quarter. The company was developing cannabis-based therapies, while continuing heavy-equipment rental in India and real-estate management in Malaysia. Reported revenue came from rental and real estate, not the cannabis pipeline.
Financial performance and position
- Revenue: $52,926, down from $288,493 in the prior-year quarter, primarily after curtailing electronics trading. Rental revenue was $10,930 and real-estate revenue $41,996.
- Profitability: Cost of revenue was $6,880, implying gross profit of $46,046 and a gross margin of approximately 87%; prior-year gross profit was $86,639, or approximately 30%. SG&A rose to $436,351 from $307,772. Operating loss was $396,269 versus $318,805; net loss attributable to common stockholders was $432,141 versus $383,566. Basic and diluted loss per share was $0.02 in both periods.
- Cash flow: Operating activities used $521,933, compared with $202,908 provided a year earlier. Investing activities used $3,851. Financing activities provided $333,206, including $647,691 from issuing stock under the ATM program. Cash fell by $192,419 to $345,610. Management reported non-GAAP cash burn of approximately $389,577.
- Liquidity: Working capital was $623,984, according to management. Current assets were $1.60 million and current liabilities $977,248. Cash was down from $538,029 at March 31; short-term investments declined from $1.88 million to zero.
- Debt and equity: Total liabilities were $3.34 million. These included $1.80 million of notes payable, $388,476 in other loans, and $175,991 in long-term borrowings. The $1.80 million note remained outstanding; the company issued 90,000 shares valued at $36,600 for quarterly interest. Shares outstanding increased from 23,265,531 at March 31 to 26,803,020 at June 30, principally reflecting stock issuances and awards.
Changes, outlook, and risks
- Revenue and cost of revenue contracted sharply as electronics trading was curtailed; management said continuing operations were real-estate management and equipment rental. Management attributed the increased quarterly loss to marketing-program expenses. SG&A also included public-company costs, including legal fees.
- The company said it expected to raise funds to expand its patent portfolio and commence medical trials for its Alzheimer’s product. Its longer-term strategy was to develop phytocannabinoid therapies; it identified four lead candidates and described clinical trials as a goal, not a committed timetable.
- Key execution and funding risks include the need for additional capital, uncertain patent registration and product development, and foreign-currency exposure because sales and operations involve INR and RM. The filing cautions that forward-looking statements are subject to risks and may differ materially from actual results.
- The company carried $430,689 of aged Cochin International Airport receivables, overdue more than a year, at full value without impairment; it said arbitration had concluded in its favor. A separate $377,795 advance related to a land transaction remained subject to settlement negotiations.
- The filing reported no significant quarterly contingencies or commitments, no material legal proceedings, and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the aged $430,689 airport receivable has been collected and whether the land-advance settlement has been resolved.
- Current cash runway, financing needs, subsequent equity issuance and dilution, and progress toward the stated Alzheimer’s trials.
- Repayment or conversion status and terms of the $1.80 million note, including its stated extension date of July 31, 2016, and continuing stock-based interest payments.
- The filing’s reported cash-burn figure and working-capital calculation against the underlying cash-flow and balance-sheet details.
- Potential recovery, share cancellation, or other outcome of the Midtown Partners transaction and related claims described in the notes.